A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 92, Issue 2, 2001, Pages 170-179

  Patton, Lauren L ^a   Bonito, Arthur J ^b   Shugars, Daniel A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN;

AIDS RELATED COMPLEX; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; METHODOLOGY; MICROBIOLOGY; OROPHARYNX; PHARYNX DISEASE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; THRUSH; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, ORAL; CLOTRIMAZOLE; DATABASES; FLUCONAZOLE; HIV SEROPOSITIVITY; HUMANS; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; OROPHARYNX; PHARYNGEAL DISEASES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; STATISTICS; TREATMENT OUTCOME;

EID: 0035434147     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2001.116600     Document Type: Article

References (33)

1. Greenspan D. Treatment of oral candidiasis in HIV infection. Oral Surg Oral Med Oral Pathol 1994;78:211-5.
2. MacPhail LA, Hilton JF, Dodd CL, Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr 1996;12:470-6.
3. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Rep 1999;48:1-59,61-6.
4. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med 1998;105:7-11.
5. Roberts IF, Roberts GJ. Relation between medicines sweetened with sucrose and dental disease. Br Med J 1979;2:14-6.
6. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991;151:2458-64.
7. Schuman P, Capps L, Peng G, Vazquez J, El-Sadr W, Goldman AI, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beim Community Programs for Clinical Research on AIDS. Ann Intern Med 1997;126:689-96.
8. Hunter KD, Gibson J, Lockhart P, Pithie A, Bagg J. Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:558-64.
9. Tumbarello M, Tacconelli E, Caldarola G, Morace G, Cauda R, Ortona L. Fluconazole resistant oral candidiasis in HIV-infected patients. Oral Dis 1997;3(Suppl 1):S110-2.
10. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.
11. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;173:219-25.
12. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.
13. Saag MS, Fessel WJ, Kaufman CA, Merrill KW, Ward DJ, Moskovitz BL, et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999;15:1413-7.
14. Lohr KN, Carey TS. Assessing 'best evidence': issues in grading the quality of studies for systematic reviews. Joint Comm J Qual Improv 1999;25:470-9.
15. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
16. Marriott DJ, Jones PD, Hoy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust 1993;158:312-6.
17. Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990;21:55-60.
18. Just-Nubling G, Gentschew G, Meissner K, Odewald J, Staszewski S, Helm EB, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991;10:917-21.
19. Phillips P, De Beule K, Frechette G, Tchamouroff S, Vandercam B, Weitner L, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998;26:1368-73.
20. De Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;1:746-8.
21. De Repentigny L, Ratelle J, Baril J-G, Frechette G, Tsoukas C, Lemieux C, et al. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. Chemotherapy 1996;42:374-83.
22. Graybill JR, Vazquez J, Darouiche RO, Morhart R, Greenspan D, Tuazon C, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998;104:33-9.
23. Pons V, Greenspan D, Lozada-Nur F, MacPhail L, Gallant JE, Tunkel A, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997;24:1204-7.
24. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr 1993;6:1311-6.
25. Murray PA, Koletar SL, Mallegol I, Wu J, Moskovitz BL. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther 1997;19:471-80.
26. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA, et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995;127:322-8.
27. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990;34:2267-8.
28. Hernandez-Sampelayo T. Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994;13:340-4.
29. Nyst MJ, Perriens JH, Kimputu L, Lumbila M, Nelson AM, Piot P. Gentian violet, ketoconazole and nystatin in oropharyngeal and esophageal candidiasis in Zairian AIDS patients. Ann Soc Belg Med Trop 1992;72:45-52.
30. De Wit S, O'Doherty E, De Vroey C, Clumeck N. Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis. J Int Med Res 1998;26:159-70.
31. Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999;21:20-5.
32. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180:448-53.
33. Freedberg KA, Scharfstein JA, Seage GR3, Losina E, Weinstein MC, Craven DE, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-6.